Skip to main content
Cidara Therapeutics, Inc. logo

Cidara Therapeutics, Inc. — Investor Relations & Filings

Ticker · CDTX ISIN · US1717572069 LEI · 549300IHQ9Z7RI1X2D22 US Manufacturing
Open in API
Filings indexed 793 across all filing types
Latest filing 2019-05-09 Interim / Quarterly Rep…
Country US United States of America
Listing US CDTX

About Cidara Therapeutics, Inc.

https://www.cidara.com/

Cidara Therapeutics, Inc. is a biotechnology company that develops targeted immunotherapies and novel anti-infectives for patients with serious diseases. The company utilizes its proprietary Cloudbreak® platform to create drug-Fc conjugates (DFCs). These DFCs are engineered as 'single molecule cocktails' by coupling targeted small molecules or peptides to a human antibody fragment (Fc). This approach is designed to directly inhibit disease targets, such as fungal or viral pathogens, while simultaneously engaging the patient's immune system. The company's focus is on developing therapies for the treatment and prevention of life-threatening infections and other serious conditions.

Recent filings

Filing Released Lang Actions
CIDARA THERAPEUTICS, INC. FORM 10-Q
Interim / Quarterly Report Q1 2019
2019-05-09 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filing dated May 9, 2019, reporting financial results for the quarter ended March 31, 2019. It includes a press release attached as Exhibit 99.1 with the financial results. The document explicitly states it is a Current Report on Form 8-K and the content is a press release announcing quarterly financial results. The length is 3893 characters, which is relatively short and the document is primarily an announcement of financial results rather than the full financial report itself. According to the definitions, an initial announcement of quarterly financial results (key highlights only) corresponds to an Earnings Release (ER). Therefore, the correct classification is Earnings Release (ER).
2019-05-09 English
DEFA14A
Remuneration Information Classification · 95% confidence The document is identified as a 'DEFA14A' filing, which corresponds to Definitive Additional Materials related to a Proxy Statement under Schedule 14A pursuant to the Securities Exchange Act of 1934. The text explicitly mentions 'Proxy Statement' and 'Schedule 14A Information,' indicating it is related to shareholder voting and governance matters. This type of filing is classified under 'Remuneration Information' or proxy-related filings. Given the specific form DEFA14A and the nature of the content, the correct classification is 'DEF 14A'. The document length is short and it is not a full report but additional proxy materials, confirming this classification with high confidence.
2019-04-26 English
DEF 14A
Proxy Solicitation & Information Statement
2019-04-26 English
FORM 4 SUBMISSION
Director's Dealing
2019-03-22 English
FORM 4 SUBMISSION
Director's Dealing
2019-03-22 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.